4.5 Review

Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices

期刊

INFLAMMATORY BOWEL DISEASES
卷 20, 期 3, 页码 564-575

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/01.MIB.0000437986.00190.71

关键词

disease activity; outcome measures; indices; histology; ulcerative colitis

资金

  1. Millennium Pharmaceuticals
  2. Merck
  3. Tillotts Pharma AG
  4. Abbott Labs
  5. Novartis Pharmaceuticals
  6. Centocor Inc.
  7. Elan/Biogen
  8. UCB Pharma
  9. Bristol-Myers Squibb
  10. Genentech
  11. ActoGenix
  12. Wyeth Pharmaceuticals Inc.
  13. Janssen-Ortho
  14. Teva Pharmaceuticals
  15. Celgene
  16. Astra Zeneca
  17. Serono
  18. Unity Pharmaceuticals
  19. Albireo Pharma
  20. Given Imaging Inc.
  21. Salix Pharmaceuticals
  22. Novonordisk
  23. GSK
  24. Prometheus Therapeutics
  25. Diagnostics
  26. Athersys
  27. Axcan
  28. Gilead
  29. Pfizer
  30. Shire
  31. Wyeth
  32. Zealand Pharma
  33. Zyngenia
  34. GiCare Pharma Inc. Sigmoid Pharma
  35. Abbott
  36. ActoGeniX NV
  37. AGI Therapeutics Inc
  38. Alba Therapeutics Corp, Albireo
  39. Alfa Wasserman
  40. Amgen
  41. AM-Pharma BV
  42. Anaphore
  43. Astellas
  44. Athersys Inc
  45. Atlantic Healthcare Ltd
  46. Aptalis
  47. BioBalance Corp
  48. Boehringer-Ingelheim
  49. Celek Pharmaceuticals
  50. Cellerix SL
  51. Cerimon Pharmaceuticals
  52. ChemoCentryx
  53. CoMentis
  54. Cosmo Technologies
  55. Coronado Biosciences
  56. Cytokine Pharmasciences
  57. Eagle Pharmaceuticals
  58. EnGene Inc
  59. Eli Lilly
  60. Enteromedics
  61. Exagen Diagnostics Inc
  62. Ferring Pharmaceuticals
  63. Flexio Therapeutics Inc
  64. Funxional Therapeutics Ltd
  65. Genzyme Corp
  66. Gilead Sciences
  67. Given Imaging
  68. Human Genome Sciences
  69. Ironwood Pharmaceuticals
  70. KaloBios Pharmaceuticals
  71. Lexicon Pharmaceuticals
  72. Lycera Corp
  73. Meda Pharmaceuticals
  74. Merck Research Laboratories
  75. Merck Serono
  76. Millenium Pharmaceuticals
  77. Nisshin Kyorin Pharmaceuticals
  78. Novo Nordisk
  79. NPS Pharmaceuticals
  80. Optimer Pharmaceuticals
  81. Orexigen Therapeutics Inc
  82. PDL Biopharma
  83. Procter and Gamble
  84. Prometheus Laboratories
  85. ProtAb Ltd
  86. Purgenesis Technologies Inc
  87. Relypsa Inc
  88. Roche
  89. Salient Pharmaceuticals
  90. Santarus
  91. Schering Plough
  92. Shire Pharmaceuticals
  93. Sigmoid Pharma Ltd
  94. Sirtris Pharmaceuticals
  95. SLA Pharma UK Ltd
  96. Targacept
  97. Therakos
  98. TxCell SA
  99. Viamet Pharmaceuticals
  100. Vascular Biogenics Ltd
  101. Warner Chilcott UK Ltd
  102. Janssen
  103. Milennium Pharmaceuticals
  104. Novartis
  105. Sigmoid Pharma
  106. Robarts Clinical Trials
  107. Santarus Inc.
  108. Prometheus labs

向作者/读者索取更多资源

Background: Ulcerative colitis (UC) is an idiopathic inflammatory disorder. Currently, the main goals of treatment are to induce and maintain clinical and/or endoscopic remission. However, evidence indicates that persistent disease activity on colonic biopsies in the setting of clinical or endoscopic remission is an independent predictor of poor outcomes. A number of previous studies have proposed histologic indices for use in specific trials of UC. The aim of this study was to systematically review the existing histological indices for UC and assess their potential use in both patient management and clinical trials. Methods: We performed a systematic review of histological indices evaluating disease activity in UC. MEDLINE (Ovid), EMBASE (Ovid), PubMed, the Cochrane Library (CENTRAL), and Digestive Diseases Week (DDW) abstracts of randomized and/or controlled trials clinical trials were searched from inception to February 2013 for applicable studies. Data from these studies were reviewed and analyzed. Results: After systematically applying inclusion criteria, we identified 108 scientific articles including 88 clinical studies and 21 related clinical reviews. Eighteen indices of histological activity in UC were identified and reviewed. Conclusions: Although multiple histological scoring indices for assessment of UC disease activity currently exist, none of these instruments were developed using a formal validation process and their operating properties remain poorly understood. Future studies are needed to address this deficiency.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据